Alternative methods of cladribine administration

References

• Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958;13:609–630.
   PubMed Web of Science ®Google Scholar
• Zakarija A, Peterson LC, Tallman MS. Splenectomy and treatments of historical interest. Best Pract Res Clin Haematol 2003;16:57–68.
   PubMed Web of Science ®Google Scholar
• Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984;310:15–18.
   PubMed Web of Science ®Google Scholar
• Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117–1121.
   PubMed Web of Science ®Google Scholar
• Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 1994;330:691–697.
   PubMed Web of Science ®Google Scholar
• Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994;14(Suppl. 1):121–125.
   PubMed Web of Science ®Google Scholar
• Lauria F, Forconi F. Towards the pharmacotherapy of hairy cell leukaemia. Expert Opin Pharmacother 2004;5:1523–1533.
   PubMed Web of Science ®Google Scholar
• Lauria F, Rondelli D, Zinzani PL, Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Leukemia 1997;11:629–632.
   PubMed Web of Science ®Google Scholar
• Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxy-adenosine in humans: alternative routes of administration. J Clin Oncol 1992;10:1514–1518.
   PubMed Web of Science ®Google Scholar
• Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 1997;15:1138–1142.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Sorensen JM, Vena DA, Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007–3015.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Hakimian D, Rademaker AW, Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1996;88:1954–1959.
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918–1926.
   PubMed Web of Science ®Google Scholar
• Hakimian D, Tallman MS, Kiley C, Peterson L. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1993;82:1798–1802.
   PubMed Web of Science ®Google Scholar
• Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891–896.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Delannoy A, Vandercam B, Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996;56:235–240.
   PubMed Web of Science ®Google Scholar
• Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: a new treatment schedule effective and safer in preventing infectious complications. Blood 1997;89:1838–1839.
   PubMed Web of Science ®Google Scholar
• Robak T, Jamroziak K, Gora-Tybor J, Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007;109:3672–3675.
   PubMed Web of Science ®Google Scholar
• Betticher DC, Ratschiller D, Hsu Schmitz SF, Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1998;9:721–726.
   Google Scholar
• Betticher DC, von Rohr A, Ratschiller D, Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma. J Clin Oncol 1998;16:850–858.
   PubMed Web of Science ®Google Scholar
• Estey EH, Kurzrock R, Kantarjian HM, Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992;79:882–887.
   PubMed Web of Science ®Google Scholar
• Jehn U, Bartl R, Dietzfelbinger H, Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Ann Hematol 1999;78:139–144.
   PubMed Web of Science ®Google Scholar
• Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999;84:22–25.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Heldal D, Hippe E, Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995;13:989–995.
   PubMed Web of Science ®Google Scholar
• Forconi F, Sozzi E, Cencini E, Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009;114:4696–4702.
   PubMed Web of Science ®Google Scholar